Last reviewed · How we verify
Tabex (cytisine)
Tabex (cytisine) is a small molecule developed by Pfizer Inc. that targets the neuronal acetylcholine receptor subunit alpha-7 to aid in smoking cessation. It is a non-nicotine prescription medication that works by activating the brain's reward system and reducing cravings for nicotine. Tabex is currently owned by Pfizer Inc. and is approved for use in certain countries, although its commercial status and availability may vary. As a smoking cessation aid, Tabex is used to help individuals overcome nicotine addiction.
At a glance
| Generic name | cytisine |
|---|---|
| Sponsor | Pfizer |
| Target | Neuronal acetylcholine receptor subunit alpha-7 |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Smoking cessation assistance
Common side effects
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- Lung Cancer Prevention Screening Programme in Italy (NA)
- Smoking Harm Reduction Using E-cigarettes and Cytisine (NA)
- Cytisine vs Nicotine Replacement Therapy (NA)
- Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation (PHASE4)
- Cytisine for Smoking Cessation (PHASE4)
- Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes (PHASE3)
- A Study of Cytisinicline for Smoking Cessation in Adult Smokers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |